HCPCS Level II code C9363 designates the Integra meshed bilayer wound matrix billed per square centimeter. This code captures the use of a biologic skin substitute product employed to promote dermal regeneration in complex or full-thickness wounds. Nationally, devices and biologic materials billed under distinct HCPCS codes are important drivers of advanced wound care costs and utilization, and accurate coding affects coverage determination and claims processing.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical indication and service context for this skin substitute, followed by benchmarks and coverage considerations commonly assessed by these payers. The publication summarizes available national pricing and utilization benchmarks where available, highlights recent policy and coverage updates that affect skin substitute billing, and outlines coding and billing nuances specific to HCPCS Level II product codes.

This report is intended to inform billing, coding, and compliance teams, as well as clinical leaders involved in wound care procurement and utilization management. It focuses on the clinical context of use, payer coverage patterns, reimbursement benchmarks, and policy developments relevant to HCPCS Level II code C9363 at a national level.